Citation Report
List of articles citing

# Clinical pharmacology of MAO inhibitors: safety and future

DOI: 10.1016/s0161-813x(03)00097-4
NeuroToxicology, 2004, 25, 215-21.

**Source:** https://exaly.com/paper-pdf/37591901/citation-report.pdf
**Version:** 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

| # | Paper | IF | Citations |
|---|---|---|---|
| 255 | Regulation of PPARgamma coactivator 1alpha (PGC-1alpha) signaling by an estrogen-related receptor alpha (ERRalpha) ligand. **2004**, 101, 8912-7 | | 167 |
| 254 | Ab initio multi-dimensional conformational analysis of R-(â)-desmethyldeprenyl: A potent neuroprotective metabolite of R-(â)-deprenyl. **2005**, 725, 75-83 | | 1 |
| 253 | Effects of 3,4-methylenedioxymethamphetamine (MDMA, 'Ecstasy') and para-methoxyamphetamine on striatal 5-HT when co-administered with moclobemide. **2005**, 1041, 48-55 | | 24 |
| 252 | Monoamine oxidase inhibitory components from the roots of Sophora flavescens. **2005**, 28, 190-4 | | 51 |
| 251 | Monoamine oxidase inhibitory constituents from the fruits of Cudrania tricuspidata. **2005**, 28, 1324-7 | | 50 |
| 250 | Neurotoxins and Drugs for the Treatment of Parkinson's Disease. Part I: Neurotoxins, Levodopa, and Agents Influencing Dopamine Metabolism (A Review). **2005**, 39, 453-465 | | 6 |
| 249 | Management of advanced Parkinson's disease and concomitant depression: a patient case. **2005**, 20, 432-5 | | |
| 248 | Sulfur-substituted alpha-alkyl phenethylamines as selective and reversible MAO-A inhibitors: biological activities, CoMFA analysis, and active site modeling. **2005**, 48, 2407-19 | | 69 |
| 247 | Effect of chronic unpredictable mild stress on brain-pancreas relative protein in rat brain and pancreas. **2005**, 165, 63-71 | | 89 |
| 246 | Human monoamine oxidase is inhibited by tobacco smoke: beta-carboline alkaloids act as potent and reversible inhibitors. **2005**, 326, 378-86 | | 199 |
| 245 | Alternatives to levodopa in the initial treatment of early Parkinson's disease. **2005**, 22, 731-40 | | 69 |
| 244 | Structural insights into monoamine oxidase inhibitory potency and selectivity of 7-substituted coumarins from ligand- and target-based approaches. **2006**, 49, 4912-25 | | 92 |
| 243 | Antidepressants and sexual dysfunction. **2006**, 114, 384-97 | | 127 |
| 242 | Impact of species-dependent differences on screening, design, and development of MAO B inhibitors. **2006**, 49, 6264-72 | | 72 |
| 241 | A QSAR model for in silico screening of MAO-A inhibitors. Prediction, synthesis, and biological assay of novel coumarins. **2006**, 49, 1149-56 | | 120 |
| 240 | Human monoamine oxidase enzyme inhibition by coffee and beta-carbolines norharman and harman isolated from coffee. **2006**, 78, 795-802 | | 98 |
| 239 | Transdermal selegiline: the new generation of monoamine oxidase inhibitors. **2006**, 11, 363-75 | | 54 |

| | | | |
|---|---|---|---|
| 238 | [Enzyme inhibitors in Parkinson treatment]. **2006**, 35, 218-25 | | |
| 237 | High-throughput screening for monoamine oxidase-A and monoamine oxidase-B inhibitors using one-step fluorescence assay. **2006**, 27, 760-6 | | 20 |
| 236 | An evaluation of potential mechanism-based inactivation of human drug metabolizing cytochromes P450 by monoamine oxidase inhibitors, including isoniazid. **2006**, 61, 570-84 | | 58 |
| 235 | Analysis of monoamine oxidase enzymatic activity by reversed-phase high performance liquid chromatography and inhibition by beta-carboline alkaloids occurring in foods and plants. *Journal of Chromatography A*, **2006**, 1120, 237-43 | 4.5 | 52 |
| 234 | Monoamine oxidase inhibitory coumarins from the aerial parts of Dictamnus albus. **2006**, 29, 1119-24 | | 45 |
| 233 | Multi-target strategies for the improved treatment of depressive states: Conceptual foundations and neuronal substrates, drug discovery and therapeutic application. **2006**, 110, 135-370 | | 433 |
| 232 | Lipophilicity plays a major role in modulating the inhibition of monoamine oxidase B by 7-substituted coumarins. **2006**, 3, 134-49 | | 43 |
| 231 | Serotonin toxicity associated with the use of linezolid: a review of postmarketing data. **2006**, 42, 1578-83 | | 166 |
| 230 | The special extract ERr 731 of the roots of Rheum rhaponticum decreases anxiety and improves health state and general well-being in perimenopausal women. **2007**, 14, 270-83 | | 18 |
| 229 | Advances in the treatment of Parkinson's disease. **2007**, 81, 29-44 | | 223 |
| 228 | Risks of combined alcohol/medication use in older adults. **2007**, 5, 64-74 | | 187 |
| 227 | Monoamine oxidase and tobacco dependence. *NeuroToxicology*, **2007**, 28, 182-95 | 4.4 | 96 |
| 226 | Solid-phase synthesis and insights into structure-activity relationships of safinamide analogues as potent and selective inhibitors of type B monoamine oxidase. **2007**, 50, 4909-16 | | 39 |
| 225 | Structures of human monoamine oxidase B complexes with selective noncovalent inhibitors: safinamide and coumarin analogs. **2007**, 50, 5848-52 | | 387 |
| 224 | Synthesis and monoamine oxidase inhibitory activity of new pyridazine-, pyrimidine- and 1,2,4-triazine-containing tricyclic derivatives. **2007**, 50, 5364-71 | | 31 |
| 223 | A validated high-performance liquid chromatographic method for the determination of moclobemide and its two metabolites in human plasma and application to pharmacokinetic studies. **2007**, 21, 958-66 | | 10 |
| 222 | Monoamine oxidase inhibition by southern African traditional medicinal plants. **2007**, 73, 384-390 | | 54 |
| 221 | Identification and occurrence of beta-carboline alkaloids in raisins and inhibition of monoamine oxidase (MAO). **2007**, 55, 8534-40 | | 49 |

| | | | |
|---|---|---|---|
| 220 | Quinolone alkaloids from evodiae fructus and their inhibitory effects on monoamine oxidase. **2007**, 30, 397-401 | | 11 |
| 219 | Use of preproenkephalin knockout mice and selective inhibitors of enkephalinases to investigate the role of enkephalins in various behaviours. **2008**, 196, 327-35 | | 22 |
| 218 | Methylpiperate derivatives from Piper longum and their inhibition of monoamine oxidase. **2008**, 31, 679-83 | | 38 |
| 217 | Synthesis, structure-activity relationships and molecular modeling studies of new indole inhibitors of monoamine oxidases A and B. **2008**, 16, 9729-40 | | 27 |
| 216 | Sensitivity of the mink (Mustela vison) liver monoamine oxidase to isoquinoline alkaloids. **2008**, 420, 161-4 | | |
| 215 | Neurodegenerative Diseases. **2008**, 565-588 | | 0 |
| 214 | Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors. **2008**, 51, 6740-51 | | 90 |
| 213 | Review on plants with CNS-effects used in traditional South African medicine against mental diseases. *Journal of Ethnopharmacology*, **2008**, 119, 513-37 | 5 | 147 |
| 212 | Serotonin-dopamine interactions: implications for the design of novel therapeutic agents for psychiatric disorders. **2008**, 172, 213-30 | | 35 |
| 211 | New oxazolidinone derivatives as antibacterial agents with improved activity. **2008**, 18, 97-121 | | 27 |
| 210 | The therapeutic potential of escitalopram in the treatment of panic disorder. **2007**, 3, 835-8 | | 2 |
| 209 | Bioactivity of Grape Chemicals for Human Health. **2009**, 4, 1934578X0900400 | | 18 |
| 208 | Antidepressant-like effects of nicotinic acetylcholine receptor antagonists, but not agonists, in the mouse forced swim and mouse tail suspension tests. *Journal of Psychopharmacology*, **2009**, 23, 797-804 | 4.6 | 86 |
| 207 | Selegiline transdermal system: a novel treatment option for major depressive disorder. **2009**, 10, 1665-73 | | 12 |
| 206 | Involvement of the serotonergic system in the anxiolytic-like effect caused by m-trifluoromethyl-diphenyl diselenide in mice. **2009**, 205, 511-7 | | 31 |
| 205 | Monoamine oxidase inhibitory activities of indolylalkaloid toxins from the venom of the colonial spider Parawixia bistriata: functional characterization of PwTX-I. **2009**, 54, 717-24 | | 21 |
| 204 | MAO-A inhibitory activity of quercetin from Calluna vulgaris (L.) Hull. *Journal of Ethnopharmacology*, **2009**, 121, 178-81 | 5 | 47 |
| 203 | Discovery of a novel class of potent coumarin monoamine oxidase B inhibitors: development and biopharmacological profiling of 7-[(3-chlorobenzyl)oxy]-4-[(methylamino)methyl]-2H-chromen-2-one methanesulfonate (NW-1772) as a highly potent, selective, reversible, and orally active monoamine oxidase B inhibitor. **2009**, 52, 6685-706 | | 83 |

| | | | |
|---|---|---|---|
| 202 | Berry anthocyanins and their aglycons inhibit monoamine oxidases A and B. **2009**, 59, 306-11 | | 61 |
| 201 | 3D-QSAR method on indole and pyrrole inhibitors of monoamine oxidase type A. **2009**, 35, 1242-1248 | | 3 |
| 200 | Nitroindazole compounds inhibit the oxidative activation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxin to neurotoxic pyridinium cations by human monoamine oxidase (MAO). **2009**, 43, 975-84 | | 14 |
| 199 | Anxiolytic-like effect of noradrenaline microinjection into the dorsal periaqueductal gray of rats. **2009**, 20, 252-9 | | 12 |
| 198 | Design of novel nicotinamides as potent and selective monoamine oxidase a inhibitors. **2010**, 18, 1659-64 | | 13 |
| 197 | Protective effect of green tea (-)-epigallocatechin-3-gallate against the monoamine oxidase B enzyme activity increase in adult rat brains. **2010**, 26, 1195-200 | | 30 |
| 196 | Monoamine levels in rat striatum after acute intraperitoneal injection of strictosidinic acid isolated from Psychotria myriantha Mull. Arg. (Rubiaceae). **2010**, 17, 289-91 | | 12 |
| 195 | New halogenated 3-phenylcoumarins as potent and selective MAO-B inhibitors. **2010**, 20, 5157-60 | | 73 |
| 194 | Synthesis and molecular modelling studies of prenylated pyrazolines as MAO-B inhibitors. **2010**, 20, 6479-82 | | 19 |
| 193 | Bioactive Chemicals and Health Benefits of Grapevine Products. **2010**, 581-620 | | 4 |
| 192 | Reversible inhibitors of monoamine oxidase-A (RIMAs): robust, reversible inhibition of human brain MAO-A by CX157. **2010**, 35, 623-31 | | 39 |
| 191 | beta-Carboline alkaloids in Peganum harmala and inhibition of human monoamine oxidase (MAO). **2010**, 48, 839-45 | | 222 |
| 190 | Antioxidant and amine oxidase inhibitory activities of hydroxyurea. **2010**, 74, 1256-60 | | 12 |
| 189 | Effects of spider venom toxin PWTX-I (6-Hydroxytrypargine) on the central nervous system of rats. **2011**, 3, 142-62 | | 5 |
| 188 | Kinetic behavior and reversible inhibition of monoamine oxidases--enzymes that many want dead. **2011**, 100, 43-64 | | 10 |
| 187 | Inhibition of the bioactivation of the neurotoxin MPTP by antioxidants, redox agents and monoamine oxidase inhibitors. **2011**, 49, 1773-81 | | 27 |
| 186 | Flavonoids and the CNS. *Molecules*, **2011**, 16, 1471-85 | 4.8 | 202 |
| 185 | Monoamine-oxidase inhibitors: pharmacological profile. **2011**, 9, 190-193 | | 1 |

| | | | |
|---|---|---|---|
| 184 | Psychotropes et sujet g. **2011**, 8, 1-13 | | 0 |
| 183 | Repeated pre-exposure to tobacco smoke potentiates subsequent locomotor responses to nicotine and tobacco smoke but not amphetamine in adult rats. **2011**, 100, 109-18 | | 14 |
| 182 | Synthesis and inhibition study of monoamine oxidase, indoleamine 2,3-dioxygenase and tryptophan 2,3-dioxygenase by 3,8-substituted 5H-indeno[1,2-c]pyridazin-5-one derivatives. *European Journal of Medicinal Chemistry*, **2011**, 46, 6104-11 | 6.8 | 15 |
| 181 | Synthesis and study of a series of 3-arylcoumarins as potent and selective monoamine oxidase B inhibitors. **2011**, 54, 7127-37 | | 119 |
| 180 | Pressor response to oral tyramine during co-administration with safinamide in healthy volunteers. **2011**, 384, 505-15 | | 16 |
| 179 | Review: Pharmacogenetic aspects of the effect of cytochrome P450 polymorphisms on serotonergic drug metabolism, response, interactions, and adverse effects. **2011**, 7, 162-84 | | 47 |
| 178 | Modern chromatographic and electrophoretic measurements of antidepressants and their metabolites in biofluids. **2011**, 25, 164-98 | | 17 |
| 177 | Synthesis and evaluation of β-carboline derivatives as potential monoamine oxidase inhibitors. **2011**, 19, 134-44 | | 71 |
| 176 | Antioxidant and semicarbazide-sensitive amine oxidase inhibitory activities of glucuronic acid hydroxamate. **2011**, 129, 423-428 | | 7 |
| 175 | Targeting monoamine oxidases with multipotent ligands: an emerging strategy in the search of new drugs against neurodegenerative diseases. **2011**, 18, 4568-87 | | 66 |
| 174 | Effects of ethanolic extract of pine needles (Pinus eldarica Medw.) on reserpine-induced depression-like behavior in male Wistar rats. **2011**, 7, 248-53 | | 14 |
| 173 | Monoamine reuptake inhibition and mood-enhancing potential of a specified oregano extract. **2011** , 105, 1150-63 | | 28 |
| 172 | History and therapeutic use of MAO-A inhibitors: a historical perspective of mao-a inhibitors as antidepressant drug. **2012**, 12, 2275-82 | | 23 |
| 171 | Antidepressant Pharmacology: Introduction for the Pharmacy Technician. **2012**, 28, 26-32 | | |
| 170 | Comparison of serotonin toxicity with concomitant use of either linezolid or comparators and serotonergic agents: an analysis of Phase III and IV randomized clinical trial data. **2012**, 67, 494-502 | | 25 |
| 169 | Predicting monoamine oxidase inhibitory activity through ligand-based models. **2012**, 12, 2258-74 | | 14 |
| 168 | Contemporary concepts in the pharmacotherapy of depression in older people. **2012**, 145, 128-135.e2 | | 3 |
| 167 | From depression to neurodegeneration and heart failure: re-examining the potential of MAO inhibitors. **2012**, 5, 413-25 | | 21 |

| | | | |
|---|---|---|---|
| 166 | Novel sulfanylphthalimide analogues as highly potent inhibitors of monoamine oxidase B. **2012**, 22, 6632-5 | | 4 |
| 165 | Sulfanylphthalonitrile analogues as selective and potent inhibitors of monoamine oxidase B. **2012**, 22, 7367-70 | | 8 |
| 164 | Anxiolytic effects of a novel herbal treatment in mice models of anxiety. **2012**, 90, 995-1000 | | 19 |
| 163 | Oxidative stress and cerebral endothelial cells: regulation of the blood-brain-barrier and antioxidant based interventions. **2012**, 1822, 822-9 | | 117 |
| 162 | Three new benzophenone glycosides with MAO-A inhibitory activity from Hypericum thasium Griseb.. **2012**, 5, 700-704 | | 13 |
| 161 | Relationship between the degree of dependence to nicotine, and the anxio-depressive levels, according to Fagerstrom test of nicotine dependence and HADS test. **2012**, 02, 235-242 | | |
| 160 | 8-Substituted 3-arylcoumarins as potent and selective MAO-B inhibitors: synthesis, pharmacological evaluation, and docking studies. **2012**, 7, 464-70 | | 44 |
| 159 | Inhibition of human monoamine oxidase A and B by 5-phenoxy 8-aminoquinoline analogs. **2012**, 22, 1701-4 | | 16 |
| 158 | Synthetic polyamines as potential amine oxidase inhibitors: a preliminary study. **2012**, 42, 913-28 | | 12 |
| 157 | Monoamine oxidases in development. **2013**, 70, 599-630 | | 47 |
| 156 | Discovery, biological evaluation, and structure-activity and -selectivity relationships of 6'-substituted (E)-2-(benzofuran-3(2H)-ylidene)-N-methylacetamides, a novel class of potent and selective monoamine oxidase inhibitors. **2013**, 56, 2651-64 | | 42 |
| 155 | A critical evaluation of reports associating ayahuasca with life-threatening adverse reactions. **2013**, 45, 179-88 | | 30 |
| 154 | Design, synthesis, and in vitro hMAO-B inhibitory evaluation of some 1-methyl-3,5-diphenyl-4,5-dihydro-1H-pyrazoles. **2013**, 23, 5128-30 | | 9 |
| 153 | Polypharmacy in Psychiatry Practice, Volume I. **2013**, | | 4 |
| 152 | Current place of monoamine oxidase inhibitors in the treatment of depression. **2013**, 27, 789-97 | | 127 |
| 151 | Development of a novel fluorine-18 labeled deuterated fluororasagiline ([(18)F]fluororasagiline-D2) radioligand for PET studies of monoamino oxidase B (MAO-B). **2013**, 21, 6634-41 | | 37 |
| 150 | Multitarget fragment-based design of novel inhibitors for AChE and SSAO/VAP-1 enzymes. **2013**, 27, 297-305 | | 1 |
| 149 | Fine molecular tuning at position 4 of 2H-chromen-2-one derivatives in the search of potent and selective monoamine oxidase B inhibitors. *European Journal of Medicinal Chemistry*, **2013**, 70, 723-39 | 6.8 | 31 |

| | | | |
|---|---|---|---|
| 148 | Ellagic acid and derivatives from Cochlospermum angolensis Welw. Extracts: HPLC-DAD-ESI/MS(n) profiling, quantification and in vitro anti-depressant, anti-cholinesterase and anti-oxidant activities. **2013**, 24, 534-40 | | 37 |
| 147 | Monoamine oxidase inhibitory activity of 3,5-biaryl-4,5-dihydro-1H-pyrazole-1-carboxylate derivatives. *European Journal of Medicinal Chemistry*, **2013**, 69, 762-7 | 6.8 | 46 |
| 146 | Monoamine oxidase A and B inhibiting effect and molecular modeling of some synthesized coumarin derivatives. **2013**, 62, 198-209 | | 22 |
| 145 | The interactions of caffeine with monoamine oxidase. **2013**, 93, 283-7 | | 49 |
| 144 | 1,5-Diphenylpenta-2,4-dien-1-ones as potent and selective monoamine oxidase-B inhibitors. *European Journal of Medicinal Chemistry*, **2013**, 59, 91-100 | 6.8 | 22 |
| 143 | Design, synthesis, in vitro MAO-B inhibitory evaluation, and computational studies of some 6-nitrobenzothiazole-derived semicarbazones. **2013**, 8, 462-74 | | 27 |
| 142 | Safety and side effects of ayahuasca in humans--an overview focusing on developmental toxicology. **2013**, 45, 68-78 | | 45 |
| 141 | Pressor response to oral tyramine and monoamine oxidase inhibition during treatment with ralfinamide (NW-1029). **2013**, 23, 315-26 | | 4 |
| 140 | Inhibition of monoamine oxidase by phthalide analogues. **2013**, 23, 1269-73 | | 16 |
| 139 | Evaluation of selective human MAO inhibitory activities of some novel pyrazoline derivatives. **2013**, 120, 863-73 | | 11 |
| 138 | Coupling of a high-resolution monoamine oxidase-A inhibitor assay and HPLC-SPE-NMR for advanced bioactivity profiling of plant extracts. **2013**, 24, 141-7 | | 37 |
| 137 | The inhibition of monoamine oxidase by esomeprazole. **2013**, 63, 462-7 | | 31 |
| 136 | Hypertensive Crisis. **2013**, 510-520 | | |
| 135 | Monoamine oxidases are mediators of endothelial dysfunction in the mouse aorta. **2013**, 62, 140-6 | | 63 |
| 134 | Adjuvant potential of selegiline in attenuating organ dysfunction in septic rats with peritonitis. *PLoS ONE*, **2014**, 9, e108455 | 3.7 | 8 |
| 133 | Striatal dopamine D2/3 receptor availability in treatment resistant depression. *PLoS ONE*, **2014**, 9, e113612 | 3.7 | 8 |
| 132 | Plant secondary metabolites- potent inhibitors of monoamine oxidase isoforms. **2014**, 14, 28-33 | | 26 |
| 131 | Monoamine Oxidase Inhibitors. **2014**, 389-390 | | 1 |

| | | | |
|---|---|---|---|
| 130 | Monoamine oxidase inhibitors: promising therapeutic agents for Alzheimer's disease (Review). *Molecular Medicine Reports*, **2014**, 9, 1533-41 | 2.9 | 114 |
| 129 | The inhibition of monoamine oxidase by phenformin and pentamidine. **2014**, 64, 454-61 | | 2 |
| 128 | Phenolic Compounds from Liquidambar formosana Fruits as Monoamine Oxidase Inhibitors. **2014**, 50, 1118-1119 | | 3 |
| 127 | Optimizing therapy for vancomycin-resistant enterococcal bacteremia in children. **2014**, 27, 517-27 | | 10 |
| 126 | Molecular modeling study on the structural basis of binding mechanism of C6-substituted phthalides with monoamine oxidases. **2014**, 23, 3624-3631 | | |
| 125 | Insight into the functional and structural properties of 3-arylcoumarin as an interesting scaffold in monoamine oxidase B inhibition. **2014**, 9, 1488-500 | | 29 |
| 124 | Monoamine oxidase (MAO) inhibitory activity: 3-phenylcoumarins versus 4-hydroxy-3-phenylcoumarins. **2014**, 9, 1672-6 | | 10 |
| 123 | Coumarin hybrids as novel therapeutic agents. **2014**, 22, 3806-14 | | 181 |
| 122 | Traditional usage, phytochemistry and pharmacology of the South African medicinal plant Boophone disticha (L.f.) Herb. (Amaryllidaceae). *Journal of Ethnopharmacology*, **2014**, 151, 12-26 | 5 | 39 |
| 121 | Labware additives identified to be selective monoamine oxidase-B inhibitors. **2014**, 19, 1409-14 | | 6 |
| 120 | A rapid thin-layer chromatography bioautographic method for detecting the monoamine oxidase inhibitors in plants. **2014**, 28, 1318-21 | | 9 |
| 119 | Total monoamine oxidase (MAO) inhibition by chestnut honey, pollen and propolis. **2014**, 29, 690-4 | | 28 |
| 118 | Alkynyl-coumarinyl ethers as MAO-B inhibitors. **2014**, 22, 1916-28 | | 30 |
| 117 | Tetralone derivatives as inhibitors of monoamine oxidase. **2014**, 24, 2758-63 | | 35 |
| 116 | Monoamine oxidase inhibitory constituents of propolis: kinetics and mechanism of inhibition of recombinant human MAO-A and MAO-B. *Molecules*, **2014**, 19, 18936-52 | 4.8 | 43 |
| 115 | Quantum chemical analysis of potential anti-Parkinson agents. **2015**, 127, 1211-1220 | | 3 |
| 114 | Synthesis and Screening of Human Monoamine Oxidase-A Inhibitor Effect of New 2-Pyrazoline and Hydrazone Derivatives. **2015**, 348, 743-56 | | 18 |
| 113 | Immunocytochemical Localization of Monoamine Oxidase Type B in Rat's Peripheral Nervous System. **2015**, 29, 521-5 | | 3 |

| | | | |
|---|---|---|---|
| 112 | 1-[2-(4-Benzyloxyphenoxy)Ethyl]Imidazole inhibits monoamine oxidase B and protects against neuronal loss and behavioral impairment in rodent models of Parkinson's disease. **2015**, 93, 1267-78 | | 10 |
| 111 | Shoot cultures of Hoppea fastigiata (Griseb.) C.B. Clarke as potential source of neuroprotective xanthones. **2015**, 69, 375-86 | | 5 |
| 110 | Monoamine oxidases are novel sources of cardiovascular oxidative stress in experimental diabetes. **2015**, 93, 555-61 | | 37 |
| 109 | Synthesis and evaluation of 6-methylcoumarin derivatives as potent and selective monoamine oxidase B inhibitors. **2015**, 6, 592-600 | | 10 |
| 108 | HPLCâDAD analysis and in vitro enzyme inhibition: An integrated approach to predict herbal binary mixture behaviour employing median effect equation. *Microchemical Journal*, **2015**, 119, 176-182 | 4.8 | 14 |
| 107 | Computer modelling of monoamine oxidases. **2015**, 9, 275-282 | | |
| 106 | Evaluation of Homobivalent Carbolines as Designed Multiple Ligands for the Treatment of Neurodegenerative Disorders. **2015**, 58, 6710-5 | | 23 |
| 105 | The separate and combined effects of monoamine oxidase inhibition and nicotine on P50 sensory gating. **2015**, 232, 1911-20 | | 2 |
| 104 | Monoamine oxidase inhibitory activity of 2-aryl-4H-chromen-4-ones. *Bioorganic Chemistry*, **2015**, 58, 72-80 | 5.1 | 34 |
| 103 | Involvement of the serotonergic system in the anxiolytic-like effect of 2-phenylethynyl butyltellurium in mice. **2015**, 277, 221-7 | | 8 |
| 102 | Synthetic and Natural Monoamine Oxidase Inhibitors as Potential Lead Compounds for Effective Therapeutics. **2016**, 16, 81-97 | | 10 |
| 101 | Effect of Alkaloids Isolated from Phyllodium pulchellum on Monoamine Levels and Monoamine Oxidase Activity in Rat Brain. **2016**, 2016, 6826175 | | 2 |
| 100 | Linezolid-induced serotonin toxicity in a patient not taking monoamine oxidase inhibitors or serotonin receptor antagonists. **2016**, 29, 214-5 | | 5 |
| 99 | Opening New Scenarios for Human MAO Inhibitors. **2016**, 16, 98-104 | | 15 |
| 98 | A Pharmacological Review of Bioactive Constituents of Paeonia lactiflora Pallas and Paeonia veitchii Lynch. **2016**, 30, 1445-73 | | 62 |
| 97 | (E)-3-Heteroarylidenechroman-4-ones as potent and selective monoamine oxidase-B inhibitors. *European Journal of Medicinal Chemistry*, **2016**, 117, 292-300 | 6.8 | 25 |
| 96 | Synthesis, ADME studies, toxicity estimation, and exploration of molecular recognition of thiophene based chalcones towards monoamine oxidase-A and B. **2016**, 5, 396-401 | | 3 |
| 95 | Recent developments on the structureâactivity relationship studies of MAO inhibitors and their role in different neurological disorders. **2016**, 6, 42660-42683 | | 64 |

| | | | |
|---|---|---|---|
| 94 | Tightrope or Slackline? The Neuroscience of Psychoactive Substances. **2016**, 37, 511-521 | | 2 |
| 93 | Pharmacodynamics. **2016**, 29-48 | | |
| 92 | Panic-modulating effects of alprazolam, moclobemide and sumatriptan in the rat elevated T-maze. **2016**, 315, 115-22 | | 3 |
| 91 | Candidate gene study reveals DRD1 and DRD2 as putative interacting risk factors for youth depression. **2016**, 244, 71-7 | | 7 |
| 90 | Exploration of chlorinated thienyl chalcones: A new class of monoamine oxidase-B inhibitors. **2016**, 91, 680-95 | | 60 |
| 89 | Cardiac Arrhythmias in Drug Abuse and Intoxication. **2016**, 151-162 | | |
| 88 | Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years. **2016**, 6, 193-213 | | 141 |
| 87 | Discovery of 3-Hydroxy-3-phenacyloxindole Analogues of Isatin as Potential Monoamine Oxidase Inhibitors. **2016**, 11, 119-32 | | 27 |
| 86 | Noradrenaline microinjected into the dorsal periaqueductal gray matter causes anxiolytic-like effects in rats tested in the elevated T-maze. **2016**, 152, 94-8 | | 1 |
| 85 | The Arrhythmic Patient in the Emergency Department. **2016**, | | |
| 84 | Letter to the Editor. **2016**, 38, 116-7 | | 1 |
| 83 | An Approach to Polysubstituted Triazipines, Thiadiazoles and Thiazoles Based on Benzopyran Moiety Through The Utility of Versatile Hydrazonoyl Halides as In Vitro Monoamine Oxidase Inhibitors. **2017**, 54, 1215-1227 | | 9 |
| 82 | DL-3-n-butylphthalide-Edaravone hybrids as novel dual inhibitors of amyloid-β aggregation and monoamine oxidases with high antioxidant potency for Alzheimer's therapy. **2017**, 27, 718-722 | | 26 |
| 81 | A Diastereoselective Multicomponent Reaction for Construction of Alkynylamide-Substituted β-Diamino Acid Derivatives To Hunt Hits. **2017**, 82, 2862-2869 | | 9 |
| 80 | A Green and Convenient Route for the Regioselective Synthesis of New Substituted 3-Aryl-5H-indeno[1,2-c]pyridazines as Potential Monoamine Oxidase Type A Inhibitors. **2017**, 70, 660 | | 6 |
| 79 | Characterization of 1-Aminobenzotriazole and Ketoconazole as Novel Inhibitors of Monoamine Oxidase (MAO): An In Vitro Investigation. **2017**, 42, 827-834 | | 6 |
| 78 | Consistency of psychotropic drug-drug interactions listed in drug monographs. **2017**, 57, 698-703.e2 | | 14 |
| 77 | Benzyloxynitrostyrene analogues - A novel class of selective and highly potent inhibitors of monoamine oxidase B. *European Journal of Medicinal Chemistry*, **2017**, 125, 1193-1199 | 6.8 | 6 |

| | | | |
|---|---|---|---|
| 76 | Monoamine Oxidase Inhibitory Activity of Biflavonoids from Branches of Garcinia gardneriana (Clusiaceae). **2017**, 12, 1934578X1701200 | | 2 |
| 75 | Synthesis of New Hydrazone Derivatives for MAO Enzymes Inhibitory Activity. *Molecules*, **2017**, 22, | 4.8 | 30 |
| 74 | Asymmetric synthesis, molecular modeling and biological evaluation of 5-methyl-3-aryloxazolidine-2,4-dione enantiomers as monoamine oxidase (MAO) inhibitors. *Bioorganic Chemistry*, **2018**, 77, 608-618 | 5.1 | 12 |
| 73 | Body fat reduction without cardiovascular changes in mice after oral treatment with the MAO inhibitor phenelzine. **2018**, 175, 2428-2440 | | 14 |
| 72 | Inhibition of human monoamine oxidase A and B by flavonoids isolated from two Algerian medicinal plants. **2018**, 40, 27-36 | | 34 |
| 71 | Analysis of monoamine oxidase (MAO) enzymatic activity by high-performance liquid chromatography-diode array detection combined with an assay of oxidation with a peroxidase and its application to MAO inhibitors from foods and plants. **2018**, 1073, 136-144 | | 21 |
| 70 | Privileged scaffolds as MAO inhibitors: Retrospect and prospects. *European Journal of Medicinal Chemistry*, **2018**, 145, 445-497 | 6.8 | 84 |
| 69 | Early Life Stress, Depression And Parkinson's Disease: A New Approach. **2018**, 11, 18 | | 47 |
| 68 | Differences in SNP genotype distributions between complex and simple suicides. **2018**, 132, 1595-1601 | | 1 |
| 67 | Design, synthesis and biochemical evaluation of novel multi-target inhibitors as potential anti-Parkinson agents. *European Journal of Medicinal Chemistry*, **2018**, 143, 1543-1552 | 6.8 | 27 |
| 66 | Design, synthesis, monoamine oxidase inhibition and docking studies of new dithiocarbamate derivatives bearing benzylamine moiety. *Bioorganic Chemistry*, **2018**, 76, 177-187 | 5.1 | 15 |
| 65 | Monoamine oxidase inhibition improves vascular function and reduces oxidative stress in rats with lipopolysaccharide-induced inflammation. **2018**, 37, 687-694 | | 12 |
| 64 | Bioprospecting of Endophytic Fungi for Bioactive Compounds. **2018**, 651-697 | | 2 |
| 63 | Synthesis and biological evaluation of new tetramethylpyrazine-based chalcone derivatives as potential anti-Alzheimer agents. **2018**, 92, 1859-1866 | | 19 |
| 62 | Novel isoxazole derivatives as potential antiparkinson agents: synthesis, evaluation of monoamine oxidase inhibitory activity and docking studies. **2019**, 28, 1488-1501 | | 9 |
| 61 | Umbelliferone derivatives exert neuroprotective effects by inhibiting monoamine oxidase A, self-amyloid-aggregation, and lipid peroxidation. *Bioorganic Chemistry*, **2019**, 92, 103293 | 5.1 | 14 |
| 60 | Discovery of monoamine oxidase inhibitors by medicinal chemistry approaches. **2019**, 10, 10-25 | | 22 |
| 59 | Systems pharmacology uncovers serotonergic pathway mediated psychotherapeutic effects of Lonicerae Japonicae Flos. **2019**, 60, 103407 | | 1 |

| | | | |
|---|---|---|---|
| 58 | Monoamine Oxidase-Related Vascular Oxidative Stress in Diseases Associated with Inflammatory Burden. **2019**, 2019, 8954201 | | 30 |
| 57 | Monoamine Oxidases (MAOs) as Privileged Molecular Targets in Neuroscience: Research Literature Analysis. **2019**, 12, 143 | | 36 |
| 56 | Lead optimization for promising monoamine oxidase inhibitor from eugenol for the treatment of neurological disorder: synthesis and in silico based study. **2019**, 13, 38 | | 6 |
| 55 | Rapid screening and identification of monoamine oxidase-A inhibitors from Corydalis Rhizome using enzyme-immobilized magnetic beads based method. *Journal of Chromatography A*, **2019**, 1592, 1-8 | 4.5 | 19 |
| 54 | Selective Inhibition of Human Monoamine Oxidase B by Acacetin 7-Methyl Ether Isolated from (Damiana). *Molecules*, **2019**, 24, | 4.8 | 21 |
| 53 | Monoamine oxidase B immobilized on magnetic nanoparticles for screening of the enzyme's inhibitors from herbal extracts. *Microchemical Journal*, **2019**, 146, 1181-1189 | 4.8 | 7 |
| 52 | The Pharmacology of Visual Hallucinations in Synucleinopathies. *Frontiers in Pharmacology*, **2019**, 10, 1379 | 5.6 | 18 |
| 51 | Hypericum perforatum in the treatment of psychiatric and neurodegenerative disorders: Current evidence and potential mechanisms of action. *Journal of Cellular Physiology*, **2019**, 234, 8496-8508 | 7 | 38 |
| 50 | The pharmacodynamic profile of "Blackadder" blackcurrant juice effects upon the monoamine axis in humans: A randomised controlled trial. *Nutritional Neuroscience*, **2020**, 23, 516-525 | 3.6 | 4 |
| 49 | A comprehensive review of monoamine oxidase inhibitors as Anti-Alzheimer's disease agents: A review. *European Journal of Medicinal Chemistry*, **2020**, 206, 112787 | 6.8 | 55 |
| 48 | Selective Interactions of -Methylated Flavonoid Natural Products with Human Monoamine Oxidase-A and -B. *Molecules*, **2020**, 25, | 4.8 | 5 |
| 47 | Discovery of Novel Procaine-Imidazole Derivative as Inhibitor of Monoamine Oxidase-B for Potential Benefit in Parkinson's Disease. *ChemistrySelect*, **2020**, 5, 10928-10932 | 1.8 | 1 |
| 46 | Genus Ruta: A natural source of high value products with biological and pharmacological properties. *Journal of Ethnopharmacology*, **2020**, 260, 113076 | 5 | 10 |
| 45 | as a potential source of neuroactive compounds to promote and restore neural functions. *Journal of Traditional and Complementary Medicine*, **2020**, 10, 309-314 | 4.6 | 6 |
| 44 | Pyridoxine-resveratrol hybrids as novel inhibitors of MAO-B with antioxidant and neuroprotective activities for the treatment of Parkinson's disease. *Bioorganic Chemistry*, **2020**, 97, 103707 | 5.1 | 15 |
| 43 | Neuroprotective Potential of Ellagic Acid: A Critical Review. *Advances in Nutrition*, **2021**, 12, 1211-1238 | 10 | 13 |
| 42 | Nonclinical Evaluation of Antibacterial Oxazolidinones Contezolid and Contezolid Acefosamil with Low Serotonergic Neurotoxicity. *Chemical Research in Toxicology*, **2021**, 34, 1348-1354 | 4 | 4 |
| 41 | Alzheimer's disease: An evolving understanding of noradrenergic involvement and the promising future of electroceutical therapies. *Clinical and Translational Medicine*, **2021**, 11, e397 | 5.7 | 8 |

| | | | |
|---|---|---|---|
| 40 | Risk assessment of ayahuasca use in a religious context: self-reported risk factors and adverse effects. *Revista Brasileira De Psiquiatria*, **2021**, 43, 362-369 | 2.6 | 2 |
| 39 | Molecular modeling and biological activity analysis of new organic-inorganic hybrid: 2-(3,4-dihydroxyphenyl) ethanaminium nitrate. *Journal of King Saud University - Science*, **2021**, 33, 101616 | 3.6 | 3 |
| 38 | Identification of monoamine oxidases inhibitory peptides from soybean protein hydrolysate through ultrafiltration purification and in silico studies. *Food Bioscience*, **2021**, 44, 101355 | 4.9 | 2 |
| 37 | If you drink alcohol, drink sensibly: a food-based dietary guideline for the elderly in South Africa. *South African Journal of Clinical Nutrition*, **2021**, 34, S15-S20 | 1.1 | |
| 36 | Semicarbazones, thiosemicarbazone, thiazole and oxazole analogues as monoamine oxidase inhibitors: Synthesis, characterization, biological evaluation, molecular docking, and kinetic studies. *Bioorganic Chemistry*, **2021**, 115, 105209 | 5.1 | 3 |
| 35 | Drug Abuse in Cardiovascular Diseases. **2012**, 393-406 | | 2 |
| 34 | Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a preliminary report. *Revista Brasileira De Psiquiatria*, **2015**, 37, 13-20 | 2.6 | 236 |
| 33 | A Comprehensive Review of Monoamine Oxidase-A Inhibitors in their Syntheses and Potencies. *Combinatorial Chemistry and High Throughput Screening*, **2020**, 23, 898-914 | 1.3 | 4 |
| 32 | Single Heterocyclic Compounds as Monoamine Oxidase Inhibitors: From Past to Present. *Mini-Reviews in Medicinal Chemistry*, **2020**, 20, 908-920 | 3.2 | 4 |
| 31 | Drug Interactions of Psychiatric and COVID-19 Medications. *Basic and Clinical Neuroscience*, **2020**, 11, 185-200 | 1.4 | 8 |
| 30 | Evaluation of Antidepressant like Effects of Ethanolic Hypericum hookerianum and its Glycosidic Flavonoid Enriched Extract in Reserpine Induced Swiss Albino Mice. *Asian Journal of Biochemistry*, **2015**, 11, 1-13 | 0.1 | 3 |
| 29 | Comparison of treatment adherence between selective serotonin reuptake inhibitors and moclobemide in patients with social anxiety disorder. *Psychiatry Investigation*, **2012**, 9, 73-9 | 3.1 | 2 |
| 28 | Mental depression: Relation to different disease status, newer treatments and its association with COVID-19 pandemic (Review). *Molecular Medicine Reports*, **2021**, 24, | 2.9 | 4 |
| 27 | Monoamine Oxidase Inhibitors and Serotonin Syndrome. **2007**, 561-577 | | |
| 26 | Antidepressants in Schizophrenia: A Place for Them?. **2013**, 211-231 | | |
| 25 | [Computer modelling of monoaminoxidases]. *Biomeditsinskaya Khimiya*, **2015**, 61, 265-71 | 0.8 | |
| 24 | Anti-depressant Activity of Standardized Macrotyloma uniflorum Extract in Experimental Models of Depression in Rats. *International Journal of Pharmacology*, **2018**, 14, 848-855 | 0.7 | 1 |
| 23 | Psychopharmacology of Anxiety Disorders. *Current Clinical Psychiatry*, **2020**, 251-267 | 0.2 | |

| | | | |
|---|---|---|---|
| 22 | Comparative Evaluation of Linezolid and Teicoplanin in the Treatment of Ventilator-Associated MRSA Pneumonia: A Single-Center Experience. *International Journal of Infection*, **2020**, 7, | 1.4 | 1 |
| 21 | Serotonin Receptors and Antidepressants: Neuroimaging Findings from Preclinical and Clinical Research. *Neuromethods*, **2022**, 373-429 | 0.4 | |
| 20 | A novel dual three and five-component reactions between dimedone, aryl aldehydes, and 1-naphthylamine: synthesis and computational studies. *Journal of Molecular Structure*, **2022**, 132569 | 3.4 | 0 |
| 19 | In vitro and in silico evaluation of Ononis isoflavonoids as molecules targeting the central nervous system.. *PLoS ONE*, **2022**, 17, e0265639 | 3.7 | 0 |
| 18 | Role of Medicinal Plants in Combating Antidepressant Induced Male Infertility. *Current Traditional Medicine*, **2022**, 08, | 0.8 | |
| 17 | Prospects of contezolid (MRX-I) against multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis.. *Drug Discoveries and Therapeutics*, **2022**, 16, | 5 | |
| 16 | Video_1.mp4. **2019**, | | |
| 15 | Video_2.mp4. **2019**, | | |
| 14 | Roles of selected non-P450 human oxidoreductase enzymes in protective and toxic effects of chemicals: review and compilation of reactions. *Archives of Toxicology*, | 5.8 | 2 |
| 13 | carboline-independent antidepressant-like effect of the standardized extract of the barks of Mimosa tenuiflora (Willd) Poir. occurs via 5-HT2A/2C receptors in mice. *Journal of Psychopharmacology*, 026988112211040 | 4.6 | 2 |
| 12 | Brain permeable curcumin-based pyrazoline analogs: MAO inhibitory and antioxidant activity. *Journal of Molecular Structure*, **2022**, 1268, 133681 | 3.4 | |
| 11 | Multiple Direct Effects of the Dietary Protoalkaloid N-Methyltyramine in Human Adipocytes. **2022**, 14, 3118 | | |
| 10 | Monoamine oxidase inhibitors: A concise review with special emphasis on structure activity relationship studies. **2022**, 242, 114655 | | 0 |
| 9 | The regulatory role of AP-2 in monoaminergic neurotransmitter systems: insights on its signalling pathway, linked disorders and theragnostic potential. **2022**, 12, | | 0 |
| 8 | Assay of MAO Inhibition by Chromatographic Techniques (HPLC/HPLC-MS). **2023**, 97-114 | | 0 |
| 7 | Cardiac MAO-A inhibition protects against catecholamine-induced ventricular arrhythmias via enhanced diastolic calcium control. | | 0 |
| 6 | Insights into the Pathophysiology of Alzheimerâ Disease and Potential Therapeutic Targets: A Current Perspective. **2022**, 1-24 | | 0 |
| 5 | Field and atom-based 3D-QSAR models of chromone (1-benzopyran-4-one) derivatives as MAO inhibitors. 1-15 | | 0 |

| | | |
|---|---|---|
| 4 | Medication Use and Sexual Activity in Older Adults. **2023**, 105-112 | 0 |
| 3 | Green Route Synthesis and Molecular Docking of Azines Using Cellulose Sulfuric Acid under Microwave Irradiation. **2023**, 13, 260 | 0 |
| 2 | Current and Future Prospects of Flavonoids for Human Immune System. **2022**, 195-211 | 0 |
| 1 | Carboline Alkaloids in Soy Sauce and Inhibition of Monoamine Oxidase (MAO). **2023**, 28, 2723 | 0 |